Delving into the Latest Updates on Daraxonrasib with Synapse

Overview

Basic Info

Drug Type

Non-degrading molecular glue

Synonyms

达拉索尼布, 达拉索拉西布, 达拉索西布

+ [5]

Target

pan-RAS+PPIA

Action

inhibitors

Mechanism

RAS(ON) inhibitor(RAS(ON) inhibitor)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

Advanced Pancreatic AdenocarcinomaPancreatic adenocarcinoma metastaticPancreatic Ductal Adenocarcinoma+ [11]

Inactive Indication

Metastatic Pancreatic Ductal Adenocarcinoma

Originator Organization

Revolution Medicines, Inc.

Active Organization

Revolution Medicines, Inc.

University of NavarraUT MD Anderson Cancer Center

+ [2]

Inactive Organization-

License Organization

BeOne Medicines Ltd.

Revolution Medicines, Inc.

Royalty Pharma Plc

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (26 Aug 2026),

Advanced Pancreatic AdenocarcinomaPancreatic adenocarcinoma metastatic

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Commissioner's National Priority Voucher (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC44H58N8O5S

InChIKeyFVICRBSEYSHKFY-UHFFFAOYSA-N

CAS Registry2765081-21-6

This Phase 1 interventional treatment study is evaluating oral daraxonrasib in participants with resectable pancreatic ductal adenocarcinoma. The study includes pre-surgery daraxonrasib treatment, surgery, adjuvant chemotherapy with or without radiation, optional adjuvant daraxonrasib, and follow-up. The protocol also includes research blood, stool, tissue, and de-identified data collection for correlative and future research.

Start Date13 Apr 2027

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+2]

NCT07819838

/ Not yet recruitingPhase 1/2IIT

A Phase 1/2 Study of Daraxonrasib (RMC-6236) in Patients With Relapsed or Refractory RAS-Driven Tumors

This phase I/II trial tests the safety, side effects, best dose and how well giving daraxonrasib works for the treatment of pediatric patients with solid tumors with RAS mutations that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Daraxonrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving daraxonrasib may be safe, tolerable and/or effective in treating patients with relapsed or refractory solid tumors with RAS mutations.

Start Date09 Apr 2027

Sponsor / Collaborator

The Children's Oncology Group Foundation, Inc.

NCT07908550

/ Not yet recruitingPhase 2

A Phase 2, Open-Label Study of Daraxonrasib Monotherapy as Second-line Treatment in Asian Patients With RAS-mutant Advanced Biliary Tract Cancer

The trial will assess the efficacy, safety, and tolerability of daraxonrasib monotherapy in Asian patients with RAS-mutated advanced biliary tract cancer in second-line treatment. The Primary Endpoint is Objective Response Rate (ORR).

Start Date01 Jan 2027

Sponsor / Collaborator

National Health Research Institutes

[+8]

100 Clinical Results associated with Daraxonrasib

Login to view more data

100 Translational Medicine associated with Daraxonrasib

Login to view more data

100 Patents (Medical) associated with Daraxonrasib

Login to view more data

111

Literatures (Medical) associated with Daraxonrasib

01 Dec 2026·BIOMEDICAL CHROMATOGRAPHY

Development and Validation of an UPLC‐QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan‐KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies

Article

Author: Fan, Ali ; Zhang, Wentao ; Liu, Yanzi ; Geng, Xuan

ABSTRACT:

Daraxonrasib, an orally administered pan‐RAS inhibitor, is undergoing clinical evaluation for pancreatic ductal adenocarcinoma, colorectal cancer, and non‐small cell lung cancer. Defining its pharmacokinetic profile is therefore critical for ongoing progress. Accordingly, a simple and sensitive UPLC‐QqQ‐MS/MS assay was developed and validated to quantify daraxonrasib in canine plasma and whole blood. Proteins were precipitated with a 20:80 (v/v) acetonitrile–methanol solution containing 0.1% formic acid. Chromatographic separation was performed on a Waters ACQUITY BEH C18 column (50 mm × 2.1 mm, 1.7 μm). The mobile phase consisted of 2 mM ammonium acetate and acetonitrile, each containing 0.1% formic acid, delivered at 0.4 mL/min. Multiple reaction monitoring transitions for daraxonrasib and the internal standard were m/z 811.5 → 680.3 and m/z 724.4 → 396.2, respectively. Calibration standards showed linear response from 1.0 to 1000 ng/mL ( r > 0.998). The assay met validation criteria for specificity, recovery, limit of quantification, accuracy, and precision. Finally, this validated method was applied to a dog pharmacokinetic study of daraxonrasib. This report outlines the drug's pharmacokinetic characteristics and supports its continued development.

01 Dec 2026·Journal of Cancer Policy

Equity in expanded access programs for daraxonrasib

Letter

Author: Ulitin, Andrei ; Fennig, Shlomit

03 Nov 2026·CANCER RESEARCH

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer

Article

Author: Ali, Mahmoud ; Sochor, Matthew A. ; Jayakrishnan, Priyanga ; Evans, Douglas B. ; Davidson, Raven ; Yuan, Jason ; Scheuber, Gabrielle ; Tsai, Susan ; McFall, Thomas ; Atallah, Nathan L. ; Johnson, Grayson ; Volkman, Brian F. ; Peterson, Francis C. ; Kurzrock, Razelle ; Chandrashekar, Naveen Kumar ; Dorbin, Daniel ; Lytle, Nikki K. ; Kamgar, Mandana ; Herrera, Juliannie ; Wittmann, Jacquelyn ; Langenheim, John F. ; Ke, Eugene ; Szabo, Aniko ; Aldakkak, Mohammed ; Hobbs, G. Aaron ; Seo, Y. David ; Sayahpour, Forough Azam ; Messerly, Charles ; Rajesh, Christabelle

Abstract:

Clinical-grade RAS inhibitors raise an unresolved question about whether KRAS alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multiselective RAS(ON) inhibitor, we compared resistance mechanisms between KRASG12D and KRASG12R, mutants with fundamentally different RAS network dynamics. Daraxonrasib inhibited mutant KRAS primarily through steric occlusion of effector binding while engaging wild-type RAS (RASWT) only modestly (∼20%). KRASG12R was marked by its inability to transactivate RASWT, and daraxonrasib-resistant KRASG12R pancreatic ductal adenocarcinoma (PDAC) cells utilized EGFR/RASWT-GTP signaling as the dominant adaptive route. In contrast, KRASG12D resistance arose through retained KRASG12D-GTP signaling, with a decrease in cyclophilin A (CypA) protein, the binding partner required for daraxonrasib activity. The shift from KRASG12R dependence to EGFR/RASWT dependence conferred sensitivity to trametinib. As clinical confirmation, a patient with KRASG12R PDAC who progressed after 10 months on daraxonrasib showed intratumoral EGFR/RASWT activation, and rapid 3D-bioprinted patient-derived tumoroid modeling predicted sensitivity to trametinib-based combination therapy. Despite the aggressive disease trajectory and lack of response to the two immediately preceding lines of therapy, sixth-line trametinib-based combination therapy achieved approximately 5 months of disease control, and this patient ultimately achieved 40 months of overall survival, far exceeding the 8 to 12 months median for metastatic PDAC. Collectively, these data establish a framework in which allele-specific RAS network topology dictates the adaptive resistance landscape, enabling rational selection of targeted therapies with meaningful clinical benefit in metastatic PDAC.

Significance::

Daraxonrasib resistance emerges through allele-specific routes, with CypA being downregulated in KRASG12D and reliance on EGFR/RASWT in KRASG12R cancer cells, informing mechanism-based therapeutic strategies for patients who progress on RAS inhibitors.

365

News (Medical) associated with Daraxonrasib

05 Nov 2026

·www.fiercepharma.com

RevMed’s Rasonque debut nets ‘eye-popping’ $198M in 5 weeks, even as exec tempers expectations

After roughly one month on the market, Revolution Medicines’ RAS inhibitor daraxonrasib is living up to its much-hyped potential, with an initial sales performance that more than one group of analysts considers “eye-popping.” Still, with some temporary launch factors at play, RevMed leadership espoused a more cautiously optimistic viewpoint as it reported third-quarter earnings Wednesday. Following an Aug. 26 approval in patients with pretreated pancreatic adenocarcinoma, daraxonrasib—now known by the brand name Rasonque— delivered $197.6 million in sales for Q3, which ended on Sept. 30. Analysts did not mince words about the stature of Rasonque’s early performance, with the team at Leerink Partners writing to clients that RevMed looks to be “pulling off the best oncology launch to date.” The nearly $200 million the drug secured in just a little over a month also comes well above the $80 million-to-$100 million haul the market had been priming for. The team at Jefferies, too, remarked that Rasonque’s sales came in more than twice that of “even the most bullish estimates,” now modeling $527 million in expected sales for the drug in the fourth quarter, a fair bit above the roughly $440 million now forecasted by Leerink. The team at Evercore ISI, for its part, claimed Rasonque’s debut was nothing short of “eye-popping.” The shop is now looking at a potential $500 million in Rasonque sales for the year’s final quarter, which it figures could segue into an expected $2.8 billion across 2027. While the sales performance to date is indeed “highly encouraging,” Anthony Mancini, RevMed’s chief global commercialization officer, took a measured approach in framing Rasonque’s future potential on a call with analysts. “With only five weeks of commercialization activity, it’s too early to draw conclusions about the normalized trajectory of launch,” he said, noting that expanded access switches and patients who’d been waiting for the therapy ahead of approval—both of which RevMed highlighted as prominent drivers of the rollout—represent “finite early launch dynamics.” “As our launch matures,” he said, “revenue will increasingly reflect ongoing treatment for newly eligible patients and ongoing treatment duration.” The U.S. rollout is nevertheless “off to a strong start,” Mancini said, reiterating RevMed’s priorities to provide a positive treatment experience, secure broad coverage and access and establish Rasonque as a new standard of care for the metastatic pancreatic cancer patients for whom the first-in-class drug is approved. So far, the company is “encouraged by the progress we’re seeing against each of these priorities,” he added. Overall, the drug’s sales haul reflects more than 5,000 patients treated in the U.S., coming over the course of just five weeks on the market. That demand was threefold, according to Manicini. These include patients who are transitioning from RevMed’s U.S. expanded access program, a “sizable cohort” of patients who’d exhausted available treatment options by the time of approval and were “waiting for a new treatment option,” and new eligible patients starting on Rasonque in the wake of the FDA nod. The transition from the expanded access program to commercial supply has now wrapped up for U.S. patients, the commercialization chief said. Though the early launch factors Mancini highlighted no doubt gave Rasonque a boost in its initial debut, analysts seemed relatively assured that the RAS inhibitor is destined for a stellar sales run in the long-term. At Leerink, the team said they estimate that the population of new second-line patients accessing Rasonque was “also robust” in the third quarter. The analysts at Jefferies had a similar take, acknowledging the early bolus for Rasonque while nevertheless espousing continued confidence in what they framed as “‘organic’ demand” for the medicine. A combination of strong science, transformative efficacy, high unmet need and successful execution by RevMed give Rasonque the potential to be “one of the best drug launches of all time,” the Jefferies team added. Still, RevMed leadership’s more cautious tone may have impacted confidence in the company’s stock, which was trading down more than 5% late Thursday morning. Rasonque has been much-ballyhooed ever since the drug’s data earned a standing ovation at the American Society of Clinical Oncology meeting in May, showing that it doubled progression-free survival following an earlier—and similarly impressive—overall survival victory in phase 3. With the green light, RevMed has also validated the broader RAS inhibition pathway, which had long been thought undruggable. The RAS protein is vital for the survival of many cancers, including most pancreatic cancers. Elsewhere, RevMed is also gearing up to launch Rasonque in the European Union, where it won the blessing of the European Medicines Agency in October. As the company waits on formal sign-off from the European Commission, launch prep and country-by-country reimbursement work is ongoing, Mancini said on RevMed’s call. While actual launch timing in Europe will depend on that Commission verdict and country-specific access accords, Mancini stressed that RevMed expects to be ready to launch as soon as its able overseas. The company is also working toward a swift rollout in Japan as Rasonque undergoes regulatory review there as well.

Drug ApprovalPhase 3ASCO

05 Nov 2026

·firstwordpharma.com

RevMed reports early momentum for Rasonque

Revolution Medicines shared the first cut of sales data for its breakthrough pancreatic cancer drug on Wednesday, sending its shares up as much as 9% during after-hours trade.The biotech won FDA approval in August for Rasonque (daraxonrasib) to treat adults with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Behind the RAS inhibitor's green light was "practice-changing" data suggesting it could help patients live twice as long as standard chemotherapy.As part of Revolution's third-quarter earnings report, it disclosed that for Rasonque's first five weeks on shelves, it brought in $197.6 million in net product revenues. More than 5000 US patients received the RAS inhibitor from its approval through Sept. 30.However, the company cautioned that the sales showing was driven by "finite early-launch dynamics, and third-quarter results should not be viewed as indicative of the launch's longer-term trajectory."Overall for the three-month period, Revolution reported a loss of $1.9 per share — beating estimates of $2.34 per share — on a quarterly net loss of $407.5 million.For an in-depth look at Rasonque's supporting data and how oncologists plan to slot the RAS inhibitor into the PDAC treatment paradigm, see –Spotlight On: Daraxonrasib set to revolutionise pancreatic cancer treatment landscapeKOL Views Q&A: Revolution's breakthrough with daraxonrasib will reverberate throughout pancreatic cancer landscape Physician Views Results: Oncologists overwhelmingly positive on second- and first-line potential of Revolution Medicines' daraxonrasib in pancreatic cancer

Drug ApprovalClinical ResultFinancial Statement

05 Nov 2026

·www.biospace.com

RevMed’s Rasonque shatters analyst estimates with $198M quarter

iStock, Afry Harvy Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter. Remarkable, historic, impressive, outstanding, stellar—these are a few of the words analysts used to describe the launch of Revolution Medicines’ pancreatic cancer medicine Rasonque. RevMed reported $198 million in revenue for the asset on Wednesday, despite only five weeks of sales following its late August approval . The value was 10 times Truist Securities’ $19 million estimate. “‘Que the duck boats,” Truist Securities quipped on Wednesday evening. That revenue stems from the more than 5,000 patients Rasonque has so far reached, RevMed’s Chief Global Commercialization Officer Anthony Mancini said on a Wednesday afternoon earnings call. The impressive launch reflects pent-up demand for the RAS inhibitor, analysts said, which arrived on the market to cheers from across the industry and beyond. Patients with pancreatic cancer had few options prior to Rasonque, with the disease among the deadliest forms of cancer . The drug was cleared in August for treating adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Rasonque arrived to “a sizable bolus of treatment option-exhausted patients,” Leerink Partners wrote on Thursday morning. Cancer RevMed could become ‘next oncology titan’ with Rasonque nod A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities. August 27, 2026 · 2 min read · Tristan Manalac Read more Specifically, demand was driven by three channels, Mancini explained. First, RevMed worked to convert participants in the Early Access Program (EAP) into commercial patients, an effort that was completed for U.S. users in the quarter. “We prioritized continuity of care and successfully supported patients in obtaining their medication through the transition,” he said. Then there were those treatment-exhausted patients, who Mancini said included patients who were later in their treatment journey and had been waiting for a new option. The third pillar was patients newly diagnosed with second-line disease, where RevMed was particularly impressed with uptake. “We’re encouraged by the speed with which we were able to begin serving patients following approval, which reflects the significant unmet need in metastatic pancreatic cancer, the strength of Rasonque’s clinical pro label, the strong launch readiness and initial execution across functions as well as payer engagement and patient support in line with our expectations,” Mancini said. But the commercial chief also sought to temper expectations about how this launch curve may flatten out. “These early results are highly encouraging. At the same time, with only five weeks of commercialization activity, it’s too early to draw conclusions about the normalized trajectory of the launch,” he said. The EAP patients and those awaiting new options in particular represent a “finite” group of patients. “As our launch matures, revenue will increasingly reflect ongoing treatment for newly eligible patients and ongoing treatment duration,” Mancini said. Earnings Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more. October 13, 2026 · 4 min read · Annalee Armstrong Read more Still, analysts were bullish on Rasonque’s growth potential. For the rest of the year, RevMed will look to bring on new patients as they advance to second line treatment for the disease. Leerink revised sales expectations to $440 million for the fourth quarter, compared to $330 million on the high end of previous estimates. RevMed is still working on insurance coverage for Rasonque as well, Mancini noted. Meanwhile, RevMed CEO Mark Goldsmith wants to make the drug available all over the world so that all patients with the difficult cancer may benefit. Europe’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion of the drug, with a formal approval decision pending with the European Medicines Agency. Digging in RevMed reported a net loss of $407.5 million for the third quarter, compared to $305.2 million for the same period a year earlier. The company had $3.7 billion in cash on hand as of September 30, not including royalty payments that began flowing from Royalty Pharma in line with Rasonque sales. The company expects to invest deeper into its RAS(ON) inhibitor portfolio while supporting launch efforts for Rasonque into 2027, according to CFO Jack Anders. Meanwhile, the biotech will also move toward adding additional lines of treatment for Rasonque, including first-line metastatic and resectable disease. Enrollment for the Phase 3 RASolute 303 trial studying the drug alone and with chemotherapy in patients with first-line metastatic pancreatic cancer recently wrapped in the U.S., Chief Development Officer Alan Sadler said on the call. And dosing has begun in another first-line Phase 3 test called RASolute 309, which features patients with RAS G12D pancreatic cancer. This study pairs Rasonque with RevMed’s up-and-coming therapy zoldonrasib. RevMed is also running two other Phase 3 trials of Rasonque, RASolute 304 in the adjuvant setting and RASolute 305 in first-line, as well as studying the drug in non-small cell lung cancer, where RAS mutations drive disease. Zoldonrasib, meanwhile, is also under investigation in colorectal cancer. RevMed has key clinical development partnerships with BeOne Medicines and Summit Therapeutics underway as well, featuring Rasonque and other pipeline assets. “Rasonque’s approval and launch mark a monumental step forward for patients living with RAS-dependent cancers and open an important new chapter for Revolution Medicines,” Goldsmith said. “With this momentum, we continue our deep commitment to discovering, developing and delivering innovative targeted medicines with the urgency patients deserve.” Cancer Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major backbone” of cancer treatment. November 2, 2026 · 6 min read · Tristan Manalac Read more

Phase 3Drug Approval

100 Deals associated with Daraxonrasib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D13265	-	-	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Advanced Pancreatic Adenocarcinoma	United States	Revolution Medicines, Inc.	26 Aug 2026
Pancreatic adenocarcinoma metastatic	United States	Revolution Medicines, Inc.	26 Aug 2026

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Ductal Adenocarcinoma	NDA/BLA	United States	Revolution Medicines, Inc.	22 Jul 2026
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	United States	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Japan	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Australia	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Belgium	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	France	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Germany	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Hong Kong	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Ireland	Revolution Medicines, Inc.	06 May 2025
RAS Mutation Non-Small Cell Lung Cancer	Phase 3	Italy	Revolution Medicines, Inc.	06 May 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06881784 (RASolve 301, ESMO2026)	Phase 3	RAS Mutation Non-Small Cell Lung Cancer RAS mutant	590	Daraxonrasib	qjhraozgre(ifsvnktvxc) = erwuawlndl mkdhjlsbxc (bswutttanv, 13.7 - NE) View more	Positive	23 Oct 2026
				Docetaxel	pyygcgiqit(coibgaywfs) = glanoulqyq fxaajcqpen (nevtyjtwbf ) View more
NCT06922591 (ESMO2026)	Phase 1/2	metastatic non-small cell lung cancer \| Methylthioadenosine phosphorylase deletion cancer MTAP deleted \| RAS mutated	50	Vopimetostat + Daraxonrasib	jxvtgzwrob(xsuppcsnnz) = zulbsydggu iflxpdzmqy (tfoocumlza ) View more	Positive	23 Oct 2026
				Vopimetostat + Zoldonrasib	jxvtgzwrob(xsuppcsnnz) = hrbsqeslez iflxpdzmqy (tfoocumlza ) View more
NCT06881784 (RASolve 301, WCLC2026)	Phase 3	Non-Small Cell Lung Cancer Second line RAS-Mutant	420	Daraxonrasib (RMC-6236)	xiodqiooon(mxmgqaxwxz) = tjibfmpqaw bgqfzxjrnk (lryqlfoqmz, 6 - 12.3)	Positive	12 Sep 2026
				Docetaxel	vhlqrrvjyk(krmqmkzyfv) = dvykzvzzmu isytcfvyyc (ssskckuvzg, 5.6 - 15.6)
NCT05379985 (RMC-6236-001, Pubmed \| N Engl J Med)	Phase 1/2	RAS Mutation Non-Small Cell Lung Cancer RAS mutations	136	Daraxonrasib 300 mg or less	wmzwybuqrj(cprwyofxht) = nhiwjhqsvu yxnzaudoik (bifugahihx ) View more	Positive	03 Sep 2026
NCT06625320 (RASolute 302, Pubmed \| N Engl J Med)	Phase 3	Metastatic Pancreatic Ductal Adenocarcinoma RAS G12 mutations	500	Daraxonrasib	kztxnevjcm(xjtomexwof) = ahpnaxurmn jauaikykoq (jkgdhauaiw ) View more	Positive	23 Jul 2026
				Chemotherapy	kztxnevjcm(xjtomexwof) = oqulhbcklc jauaikykoq (jkgdhauaiw ) View more
NCT06625320 (RASolute 302, ASCO2026)	Phase 3	Pancreatic adenocarcinoma metastatic Second line RAS G12 \| RAS G13 \| Q61	500	Daraxonrasib 300 mg PO QD	ucuctyefdt(anawegmosl) = jpeiljpiyt hfdqawgcqg (wzpwwlsoth, 10.0–NE) View more	Positive	29 May 2026
				Investigator’s choice of SOC cytotoxic chemo	ucuctyefdt(anawegmosl) = ysyduxxgvd hfdqawgcqg (wzpwwlsoth, 5.4–8.2) View more
NCT05379985 (RMC-6236-001, NEWS 1 \| NEWS 2 \| NEWS 3 \| Literature) Manual	Phase 1/2	KRAS mutant pancreatic ductal adenocarcinoma RAS mutations	168	Daraxonrasib (RAS-mutated Pancreatic Ductal Adenocarcinoma)	aevvofuqcb(sxkqrpckxk) = jqporivcnr imyacnnywt (ilgjxrhdge ) View more	Positive	14 May 2026
				Daraxonrasib (RAS G12 mutations)	vhgaeclpre(ijerasqgog) = bdfpfowyxi hjrfuhcqgg (amiiubqrrn, 17 - 56) View more
NCT05379985 (AACR2026)	Phase 1/2	Pancreatic adenocarcinoma metastatic First line RAS mutations	40	Daraxonrasib 300 mg QD	jkiemkgiwr(zmtlfqzzcb) = etfdblzcci unxlapqnka (zslwqepusi, 79 - 98) View more	Positive	21 Apr 2026
NCT06881784 (RASolve 301, AACR2026)	Phase 3	RAS mutation	420	Daraxonrasib	ecbsdjibst(blwddflebe) = pzcoowbklf mngvmhmiqn (ejcslkslgk, 6 - 12.3) View more	Positive	21 Apr 2026
				Docetaxel	vblkzfcdiz(styvyjrvgs) = yyzewanngu pgdcbbsumg (phthkmnsdv, 8.1 - 10.8) View more
NCT06445062 (AACR2026)	Phase 1/2	Pancreatic adenocarcinoma metastatic First line RAS mutations	40	Daraxonrasib + gemcitabine/nab-paclitaxel (GnP)	ulopgdkmiy(cygetwcakr) = amdjzpkrfs bldfieqgeu (paedyafpob, 76 - 97) View more	Positive	21 Apr 2026
				Daraxonrasib + gemcitabine/nab-paclitaxel (GnP) (Pts with measurable disease at baseline and either had ≥ 1 post-baseline tumor assessment or had clinical progression or death prior to such assessment.)	ulopgdkmiy(cygetwcakr) = hcegirtubk bldfieqgeu (paedyafpob, 79 - 98) View more